Inductively coupled plasma mass spectroscopy quantitation of platinum-DNA adducts in peripheral blood leukocytes of patients receiving cisplatin- or carboplatin-based chemotherapy

Clinical Cancer Research

Volumn 2, Issue 11, 1996, Pages 1829-1835

  Bonetti, Andrea ^a   Apostoli, Piero ^b   Zaninelli, Marta ^a   Pavanel, Flavia ^a   Colombatti, Marco ^c   Cetto, Gian Luigi ^a   Franceschi, Tiziano ^a   Sperotto, Loris ^a   Leone, Roberto ^c  

^a UNIVERSITY HOSPITAL OF VERONA   (Italy)

^b UNIVERSITY OF BRESCIA   (Italy)

^c UNIVERSITY OF VERONA   (Italy)

Author keywords

[No Author keywords available]

Indexed keywords

BLEOMYCIN; CARBOPLATIN; CISPLATIN; CYCLOPHOSPHAMIDE; DOXORUBICIN; ETOPOSIDE; FLUOROURACIL; IFOSFAMIDE; MITOMYCIN C; VINBLASTINE;

ADULT; AGED; ARTICLE; CANCER; CANCER CHEMOTHERAPY; DNA ADDUCT; FEMALE; HUMAN; HUMAN CELL; INTRAVENOUS DRUG ADMINISTRATION; LEUKOCYTE; MAJOR CLINICAL STUDY; MALE; MASS SPECTROMETRY; PRIORITY JOURNAL; QUANTITATIVE ASSAY;

ADULT; AGED; ANTINEOPLASTIC AGENTS; CARBOPLATIN; CISPLATIN; DNA ADDUCTS; FEMALE; HUMANS; LEUKOCYTES, MONONUCLEAR; MALE; MASS SPECTROMETRY; MIDDLE AGED; NEOPLASMS; PLATINUM;

EID: 0029824906     PISSN: 10780432     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (31)

1. Reed, E. Platinum analogs, In: V. T. De Vita, S. Hellman, and S. A. Rosenberg (eds.), Cancer: Principles and Practice of Oncology, Vol 1, pp. 390-400. Philadelphia: J B. Lippincott, 1993
2. Knox, R. J., Friedlos, F., Lydall, D. A., and Roberts, J. J. Mechanism of cytotoxicity of anticancer platinum drugs: evidence that cis-diamminedichloroplatinum (II) and cis-diammine- (1, 1 -cyclobutanedicarboxylato) platinum (II) differ only in the kinetics of their interaction with DNA. Cancer Res., 46: 1972-1979, 1986.
3. Reed, E., Yuspa, S. H., Zwelling, L. A., Ozols, R. F., and Poirier, M. C. Quantitation of cis-diammtnedichloroplatinum (II) (cisplatin)-DNA-intrastrand adducts in testicular and ovarian cancer patients receiving cisplatin chemotherapy. J Clin. Invest., 77: 545-550, 1986.
4. Blommaert, F. A., Michael, C., Terheggen, P. M. A. B., Muggia, F. M., Kortes, V , Schornagel, J. H., Hart, A. A. M., and den Engelse, L. Drug-induced DNA modification in buccal cells of cancer patients receiving carboplatin and cisplatin combination chemotherapy, as de termined by an immunocytochemical method: interindividual variation and correlation with disease response. Cancer Res., 53: 5669-5675, 1993.
5. Fichtinger-Schepman, A. M J., van Oosterom, A. T., Lohman, P. H. M., and Berends, F cis-Diamminedichloroplatinum (II)-induced DNA adducts in peripheral leukocytes from seven cancer patients: quantitative immunochemical detection of the adduct induction and removal after a single dose of cis-diamminedichloroplatinum (II). Cancer Res., 47: 3000-3004, 1987.
6. Reed, E., Sauerhoff, S., and Poirier, M. C. Quantitation of platinum-DNA binding after therapeutic levels of drug exposure: a novel use of graphite furnace spectrometry. Atomic Spectroscopy, 9: 93-95, 1988.
7. Reed, E., Ozols, R. F., Tarone, R., Yuspa, S. H., and Poirier, M. C. Platinum-DNA adducts in leukocyte DNA correlate with disease response in ovarian cancer patients receiving platinum-based chemotherapy. Proc. Natl. Acad. Sci. USA, 84: 5024-5028, 1987.
8. Parker, R. J., Gill, I., Tarone, R., Vionnet, J. A., Grunberg, S., Muggia, F. M., and Reed, E. Platinum-DNA damage in leukocyte DNA of patients receiving carboplatin and cisplatin chemotherapy, measured by atomic absorption spectrometry. Carcinogenesis (Lond.), 12: 1253-1258, 1991.
9. Reed, E., Parker, R. J , Gill, I, Bicher, A., Dabholkar, M., Vionnet, J A., Bostick-Bruton, F., Tarone, R., and Muggia, F. M. Platinum-DNA adduct in leukocyte DNA of a cohort of 49 patients with 24 different types of malignancies. Cancer Res., 53: 3694-3699, 1993.
10. Schellens, J. H. M., Ma, J., Planting, A. S. T., van der Burg, M. E. L., Schmitz, P. I. M., Stoter, G., and Verweij, J. Exposure to cisplatin and WBC DNA adduct formation determine the likelihood of response in solid tumor patients, which enables adaptive intra-patient dose-escalation. In. Proceedings of the 7th International Symposium on Platinum and Other Metal Coordination Compounds in Cancer Chemotherapy Abstract 055. Amsterdam, the Netherlands. March 1-4, 1995.
11. Fichtinger-Schepman, A. M. J., van Oosterom, A. T., Lohman, P. H. M., and Berends, F. Interindividual human variation in cisplatinum sensitivity, predictable in an in vitro assay? Mutat. Res., 190: 59-62, 1987
12. Fichtinger-Schepman, A. M. J., van der Velde-Visser, S. D., van Dijk-Knijnenburg, H. C. M., van Oosterom, A. T., Baan, R. A., and Berends, F. Kinetics of the formation and removal of cisplatin-DNA adducts in blood cells and tumor tissue of cancer patients receiving chemotherapy: comparison with in vitro adduct formation. Cancer Res., 50: 7887-7894, 1990.
13. Oshita, F., Yamamoto, N., Fukuda, M., Ohe, Y., Tamura, T., Eguchi, K., Shinkai, T., and Saijo, N. Correlation of therapeutic outcome in non-small lung cancer and DNA damage assayed by polymerase chain reaction in leukocytes damaged in vitro. Cancer Res., 55: 2334-2337, 1995.
14. Vanhoe, H. A review of the capabilities of ICP-MS for trace element analysis in body fluids and tissues. J. Trace Elem Electrolytes Health Dis., 7: 131-139, 1993.
15. Miller, A. B., Hoogstraten, B., Staquet, M., and Winkler, A. Reporting results of cancer treatment. Cancer (Phila.), 47: 207-214, 1981.
16. Hryniuk, W., and Bush, H The importance of dose intensity of chemotherapy of metastatic breast cancer J. Clin. Oncol., 2: 1281-1288, 1984.
17. Chatelut, E., Canal, P., Brunner, V., Chevreau, C., Pujol, A., Boneu, A., Roché, H., Houin, G., and Bugat, R. Prediction of carboplatin clearance from standard morphological and biological patient characteristics J. Natl. Cancer Inst., 87: 573-580, 1995
18. Delves, H. T. The use of inductively coupled plasma source mass spectrometry (ICP-MS) for analysis in blood. In: D C. H. McBrien and T. F. Slater (eds.), Biochemical Mechanisms of Platinum Anti-Tumor Drugs, pp 347-350. Oxford, United Kingdom: IRL Press, 1986.
19. Tothill, P., Matheson, L. M., Smyth, J. F., and McKay, K. Inductively coupled plasma mass spectrometry for the determination of platinum in animal tissues and a comparison with atomic absorption spectrometry. J. Anal. At. Spectrom., 5: 619-622, 1990.
20. Perera, F. P., Motzer, R J., Tang, D., Reed, E., Parker, R., Warburton, D., O'Neill, P., Albertini, R., Bigbee, W. L., Jensen, R. H., Santella, R., Tsai, W-Y., Simon-Cereijido, G., Randall, C., and Bosl, G. Multiple biological markers in germ cell tumor patients treated with platinum-based chemotherapy Cancer Res., 52: 3558-3565, 1992.
21. Ma, J., Verweij, J., Planting, A., deBoer-Dennert, M., van Ingen, H. E., van der Burg, M. E. L., Stoter, G., and Schellens, J. H. M. Current sample handling methods for measurement of platinum-DNA adducts in leukocytes in man lead to discrepant results in DNA adduct levels and DNA repair. Br. J. Cancer, 71: 512-517, 1995.
22. Motzer, R. J., Reed, E., Perera, F., Tang, D., Shamkhani, H., Poirier, M. C., Tsai, W. Y., Parker, R. J., and Bosl, G. Platinum-DNA adducts assayed in leukocytes of patients with germ cell tumors measured by atomic absorbance spectrometry and enzyme-linked immunosorbent assay. Cancer (Phila.), 73: 2843-2852, 1994.
23. Gupta-Burt, S., Shamkhani, H., Reed, E., Tarone, R. E., Allegra, C. J., Pai, L. H., and Poirier, M. C. Relationship between patient response in ovarian and breast cancer and platinum drug-DNA adduct formation. Cancer Epidemiol., Biomarkers, & Prev., 2: 229-234, 1993.
24. Mong, S., Huang, C. H., Pestayko, A. W., and Crooke, S. T. Effects of second-generation platinum analogs on isolated PM-2 DNA and their cytotoxicity in vitro and in vivo. Cancer Res., 40: 3318-3324, 1980.
25. Reed, E., Gupta-Burt, S., Katz, D., and Poirier, M. C. Platinum-DNA adduct measured at autopsy in multiple human tissues. Proc. Am. Assoc. Cancer Res., 30: 1099, 1989.
26. Poirier, M. C., Reed, E., Litterst, C. L., Katz, D., and Gupta-Burt, S. Persistence of platinum-ammine-DNA adducts in gonads and kidneys of rats and multiple tissues from cancer patients. Cancer Res., 52: 149-153, 1992.
27. 6-alkylguanine alkyltransferase-directed DNA repair in metastatic colon cancers. J. Clin. Oncol., 13: 2301-2308, 1995.
28. Armstrong, S. G., Browman, G. P., Benger, A. M., Meyer, R. M., McKay, K. L., and Singh, G. Relation between platinum-DNA adducts and complete remission in adult acute nonlymphocytic leukemia. Leuk. Res., 18: 659-664, 1994.
29. Litterst, C. L. Plasma pharmacokinetics, urinary excretion, and tissue distribution of platinum following i.v. administration of cyclobutanedicarboxylatoplatinum(II) and cis-platinum to rabbits. In: M. P. Hacker, E. B. Douple, and I. H. Krakoff (eds.), Platinum Coordination Complexes in Cancer Chemotherapy, pp. 71-81. Boston: Martinus Nijhoff Publishing, 1984.
30. Fichtinger-Schepman, A. M. J., Vendrik, C. P. J., van Dijk-Knijnenburg, W. C. M., de Jong, W. H., van der Minnen, A. C. E., Claessen, A. M. E., van der Velde-Visser, S. D., de Groot, G., Wubs, K. L., Steerenberg, P. A., Schornagel, J. H., and Berends, F. Platinum concentrations and DNA adduct levels in tumors and organs of cisplatin-treated LOU/M rats inoculated with cisplatin-sensitive or cisplatin-resistant immunoglobulin M immunocytoma. Cancer Res., 49: 2862-2867, 1989.
31. Parker, R. J., Dimery, I. W., Dabholkar, M., Vionnet, J., and Reed, E. Platinum-DNA adduct in head and neck cancer patients receiving cisplatin and carboplatin chemotherapy. Int. J. Oncol., 3: 331-335, 1993.